Filing Flows › Bolt Biotherapeutics (BOLT) › Q4 2025
Bolt Biotherapeutics (BOLT) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 12, 2026
Bolt Biotherapeutics (BOLT) reported revenue of $2.5M for the fourth quarter 2025 (Q4 2025) and +15% from the quarter before. Operating margin was -283.4%, net loss $6.6M (265.2% of revenue).
Bolt Biotherapeutics, Q4 2025: revenue $2.5M, operating margin -283.4%, net loss $6.6M, operating cash flow −$7.2M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.5M | +15% | — |
| Operating profit | −$7.1M | — | — |
| Net earnings | −$6.6M | — | — |
| Operating cash flow | −$7.2M | — | — |
What changed
Revenue was $2.5M in Q4 2025, up 15% from the previous quarter.
Operating costs exceeded revenue by $7.1M, an operating margin of -283.4%. The quarter ended with a net loss of $6.6M, narrower than the previous quarter's $7.1M loss.
Operating cash flow was −$7.2M. Non-cash charges added back $255K of depreciation and amortization and $1.0M of share-based compensation. Working capital and other items used $1.8M.
Questions
What was Bolt Biotherapeutics' revenue in the fourth quarter 2025?
Bolt Biotherapeutics (BOLT) reported revenue of $2.5M for the fourth quarter 2025 (Q4 2025) and +15% from the quarter before.
Was Bolt Biotherapeutics profitable in the fourth quarter 2025?
Operating loss was $7.1M (-283.4% of revenue) and net loss $6.6M.